

Resource Summary Report

Generated by SPARC SAWG on Sep 13, 2026

Prize4Life

RRID:SCR_006558

Type: Tool

Proper Citation

Prize4Life (RRID:SCR_006558)

Resource Information

URL: <http://www.prize4life.org/>

Proper Citation: Prize4Life (RRID:SCR_006558)

Description: Prize4Life is a 501(c)(3) nonprofit organization dedicated to accelerating the discovery of treatments and cures for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease). Our mission is to accelerate the discovery of a treatment and a cure for ALS by using powerful incentives to attract new people and new ideas and to leverage existing efforts and expertise in the ALS field. Our Values: * Patients first. Avichai Kremer, one of the Harvard Business School students who founded Prize4Life, was diagnosed with ALS in 2004. We therefore know the disease firsthand and have a sense of urgency to find a treatment. We value patients and their viewpoints. Patients, please tell us what you think. * Global awareness. We plan to push ALS to the forefront of fatal disease issues. We need your help in order to do this. Get involved. * New people and new ideas. We believe important breakthroughs in ALS may reside in the minds and laboratories of people who are not currently researching the disease. Our platform is a bridge for reaching these people. Enter the competition. * Results. Research is traditionally funded upfront, before an idea is even tested. Our prize model ensures that only clear research results, vetted by a team of scientific advisors, are rewarded. grants; funding resource;

Synonyms: Prize4Life

Resource Type: data or information resource, funding resource, portal, topical portal

Resource Name: Prize4Life

Resource ID: SCR_006558

Alternate IDs: nif-0000-00493

Record Creation Time: 20220129T080236+0000

Record Last Update: 20260912T195641+0000

Ratings and Alerts

No rating or validation information has been found for Prize4Life.

No alerts have been found for Prize4Life.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Dandl S, et al. (2024) Heterogeneous treatment effect estimation for observational data using model-based forests. *Statistical methods in medical research*, 33(3), 392.

Cox LM, et al. (2022) The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis. *Microbiome*, 10(1), 47.

Gordon J, et al. (2019) Insights into Amyotrophic Lateral Sclerosis from a Machine Learning Perspective. *Journal of clinical medicine*, 8(10).

Karanevich AG, et al. (2018) Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. *BMC medical research methodology*, 18(1), 19.

Hilton JB, et al. (2017) Cull(atSm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. *Scientific reports*, 7, 42292.

Huang Z, et al. (2017) Complete hazard ranking to analyze right-censored data: An ALS survival study. *PLoS computational biology*, 13(12), e1005887.

Ong ML, et al. (2017) Predicting functional decline and survival in amyotrophic lateral sclerosis. *PloS one*, 12(4), e0174925.

Borel F, et al. (2016) Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. *Human gene therapy*, 27(1), 19.

Williams JR, et al. (2016) Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. *Neurobiology of disease*, 89, 1.

Xu X, et al. (2015) A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. *Disease models & mechanisms*, 8(8), 831.